Ginkgo Bioworks Holdings, Inc.

NYSE:DNA Stock Report

Market Cap: US$349.8m

Ginkgo Bioworks Holdings Valuation

Is DNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DNA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DNA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DNA?

Key metric: As DNA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DNA. This is calculated by dividing DNA's market cap by their current revenue.
What is DNA's PS Ratio?
PS Ratio1.7x
SalesUS$217.95m
Market CapUS$349.81m

Price to Sales Ratio vs Peers

How does DNA's PS Ratio compare to its peers?

The above table shows the PS ratio for DNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
VHI Valhi
0.4xn/aUS$758.6m
RYAM Rayonier Advanced Materials
0.4x3.3%US$587.3m
ECVT Ecovyst
1.4x5.2%US$946.1m
ARQ Arq
3x18.4%US$318.2m
DNA Ginkgo Bioworks Holdings
1.7x1.8%US$349.8m

Price-To-Sales vs Peers: DNA is expensive based on its Price-To-Sales Ratio (1.7x) compared to the peer average (1.3x).

Price to Sales Ratio vs Industry

How does DNA's PS Ratio compare vs other companies in the US Chemicals Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
TSE Trinseo
0.04x5.0%US$122.49m
ALTO Alto Ingredients
0.1x3.1%US$108.84m
BON Bon Natural Life
0.2xn/aUS$6.27m
ABLT American Biltrite
0.02xn/aUS$2.91m
DNA 1.7xIndustry Avg. 1.4xNo. of Companies17PS01.22.43.64.86+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DNA is expensive based on its Price-To-Sales Ratio (1.7x) compared to the US Chemicals industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is DNA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DNA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio6.6x

Price-To-Sales vs Fair Ratio: DNA is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (6.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DNA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.18
US$8.20
+14.2%
19.5%US$10.00US$6.00n/a5
Nov ’25US$7.75
US$8.80
+13.5%
16.7%US$10.00US$7.00n/a5
Oct ’25US$7.60
US$14.80
+94.7%
85.6%US$40.00US$7.00n/a5
Sep ’25US$6.69
US$36.80
+450.1%
118.0%US$120.00US$7.00n/a5
Aug ’25US$14.80
US$48.33
+226.6%
93.6%US$120.00US$8.00n/a6
Jul ’25US$12.93
US$55.33
+328.0%
72.8%US$120.00US$8.00n/a6
Jun ’25US$21.14
US$57.33
+171.2%
66.5%US$120.00US$20.00n/a6
May ’25US$33.68
US$76.80
+128.0%
40.5%US$120.00US$40.00n/a5
Apr ’25US$44.80
US$78.80
+75.9%
36.7%US$120.00US$44.00n/a5
Mar ’25US$51.60
US$86.80
+68.2%
38.4%US$120.00US$44.00n/a5
Feb ’25US$50.80
US$123.33
+142.8%
62.4%US$280.00US$44.00n/a6
Jan ’25US$67.60
US$137.67
+103.6%
58.8%US$280.00US$50.00n/a6
Dec ’24US$57.20
US$135.14
+136.3%
55.6%US$280.00US$50.00n/a7
Nov ’24US$54.40
US$160.75
+195.5%
80.0%US$480.00US$50.00US$7.758
Oct ’24US$72.40
US$160.75
+122.0%
80.0%US$480.00US$50.00US$7.608
Sep ’24US$90.00
US$160.75
+78.6%
80.0%US$480.00US$50.00US$6.698
Aug ’24US$93.60
US$169.50
+81.1%
75.5%US$480.00US$50.00US$14.808
Jul ’24US$74.40
US$169.50
+127.8%
75.5%US$480.00US$50.00US$12.938
Jun ’24US$67.20
US$178.25
+165.3%
68.3%US$480.00US$70.00US$21.148
May ’24US$47.20
US$180.75
+282.9%
66.5%US$480.00US$70.00US$33.688
Apr ’24US$53.20
US$185.75
+249.2%
63.7%US$480.00US$70.00US$44.808
Mar ’24US$56.00
US$197.00
+251.8%
59.0%US$480.00US$80.00US$51.608
Feb ’24US$80.00
US$197.00
+146.3%
59.0%US$480.00US$80.00US$50.808
Jan ’24US$67.60
US$202.00
+198.8%
55.4%US$480.00US$120.00US$67.608
Dec ’23US$79.20
US$232.67
+193.8%
54.5%US$480.00US$120.00US$57.209
Nov ’23US$109.60
US$304.25
+177.6%
52.2%US$580.00US$120.00US$54.408

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Trinseo

US$115.1m

Operates as a specialty material solutions provider in the United States, Europe, the Asia-Pacific, and internationally.

TSE

US$3.46

7D

-5.2%

1Y

-46.7%

Huntsman

US$3.4b

Manufactures and sells diversified organic chemical products worldwide.

HUN

US$19.62

7D

1.7%

1Y

-21.3%

Chemtrade Logistics Income Fund

CA$1.4b

Offers industrial chemicals and services in Canada, the United States, and South America.

CGIF.F

CA$8.19

7D

3.3%

1Y

29.8%